TRPM8 and prostate cancer: Here, by applying a multidisciplinary approach to a tailored in vitro/ex vivo preclinical platform, we demonstrate that pharmacological activation of TRPM8 in primary and hormone naïve metastatic models of PCa sensitizes prostate cancer cells to standard-of-care clinical protocols for the treatment of locally advanced PCa, thus pointing out the relevance of ion channels as therapeutic targets in oncology.